3 research outputs found

    Protein Functional Families to characterise drug-target interactions.

    Get PDF
    The quest for “magic bullets” has been the driving force in drug discovery during the last two decades. However, the increasing rate of drug failure over this period has occurred concurrently with the assumption that a drug is a selective ligand for a single target. It now seems likely that polypharmacology is the rule rather than the exception [1]. Our previous research shows that protein domains are a good proxy for drug targets, and that drug polypharmacology emerges as a consequence of the multi-domain composition of proteins [2]. In this study, we investigate further the idea that the domain is the druggable entity within a protein target. We have identified a specific class of domains (CATH Functional Families) as the best currently available for identifying drug-target interactions. We show how this opens a new direction in target identification with potential application in drug repurposing.1. Hopkins, AL. (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol; 4: 682 2. Moya-García AA & Ranea JAG (2013) Insights into polypharmacology from drug-domain associations. Bioinformatics 29: 1934–1937)Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech. Universidad de Granad

    Acceleration and Verification of Virtual High-throughput Multiconformer Docking

    Get PDF
    The work in this dissertation explores the use of massive computational power available through modern supercomputers as a virtual laboratory to aid drug discovery. As of November 2013, Tianhe-2, the fastest supercomputer in the world, has a theoretical performance peak of 54,902 TFlop/s or nearly 55 thousand trillion calculations per second. The Titan supercomputer located at Oak Ridge National Laboratory has 560,640 computing cores that can work in parallel to solve scientific problems. In order to harness this computational power to assist in drug discovery, tools are developed to aid in the preparation and analysis of high-throughput virtual docking screens, a tool to predict how and how well small molecules bind to disease associated proteins and potentially serve as a novel drug candidate. Methods and software for performing large screens are developed that run on high-performance computer systems. The future potential and benefits of using these tools to study polypharmacology and revolutionizing the pharmaceutical industry are also discussed
    corecore